OTCM
HYDI
Market cap715kUSD
Oct 02, Last price
0.15USD
Name
Hydromer Inc
Chart & performance
P/E
—
P/S
0.19
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-2.86%
Revenues
4m
+2.65%
Net income
-2m
L-40.91%
CFO
-341k
L+614.58%
Dividend
Oct 09, 20180.25 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hydromer, Inc. (HYDI) is a company dedicated to the full lifecycle of hydrophilic polymer-based solutions, from invention and patenting to manufacturing and global sales of both products and services. Its operations are divided into two primary divisions: Polymer Research and Medical Products. The company's diverse offerings include specialized medical coatings and related services, medical hydrogel formulations, and key ingredients for cosmetic products. Hydromer also develops advanced coatings for condensation control (specifically anti-fog and anti-frost applications), manufactures various cosmetics and personal care items, and provides protective coatings for watercraft hulls. Additionally, it extends its expertise through engineering and contract coating services. Established in 1980 and headquartered in Branchburg, New Jersey, Hydromer serves a broad spectrum of industries, including the medical, cosmetics, animal health, and industrial sectors.
Key people
Peter M. von Dyck
President, Chief Executive Officer · since 2018
Chief Financial Officer, Vice President - Finance, Treasurer · since 2001
Martin C. Dyck
Executive Vice President - Operations; President of Biosearch Medical Products · since 2001
John Konar
Vice President - Quality Assurance, Director - Human Resources · since 2004
Ursula M. Dyck
Director · since 1980
Manfred F. Dyck
Chairman of the Board, Executive Vice President - R&D · since 2018
Dieter Heinemann
Director · since 1991
George A. Ziets
Director · since 2009
Robert H. Bea
Independent Director · since 1996
Maxwell Borow
Independent Director · since 1990
Frederick L. Perl
Independent Director · since 2000
Michael F. Ryan
Independent Director · since 2003
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||